Palbociclib CDK (cyclin-dependent kinase) inhibitor

PD-0332991 - PD0332991 - PD 0332991 - Ibrance - palbociclib

Advanced breast cancer (metastatic)

All type of patients:  6 trials  - PEARL - PALOMA-4 - PALOMA-2 - PALOMA 3 - PENELOPE-B - PALOMA 1/TRIO-18

palbociclib vs placebo

No demonstrated result

palbociclib + letrozole vs letrozole alone

No demonstrated result

palbociclib + exemestane vs capecitabine

No demonstrated result

palbociclib + fulvestrant vs fulvestrant alone

progression or death (progression free survival PFS) by 58% (fully demonstrated)

palbociclib + letrozole vs letrozole alone

progression or death (progression free survival PFS) by 44% (fully demonstrated)

See more clinical conditions

HR+ HER2-:  5 trials  - PEARL - PALOMA-4 - PALOMA-2 - PALOMA 3 - PALOMA 1/TRIO-18

palbociclib + letrozole vs letrozole alone

No demonstrated result

palbociclib + exemestane vs capecitabine

No demonstrated result

palbociclib + fulvestrant vs fulvestrant alone

progression or death (progression free survival PFS) by 58% (fully demonstrated)

palbociclib + letrozole vs letrozole alone

progression or death (progression free survival PFS) by 44% (fully demonstrated)